SCHEMBL4895489

SCHEMBL4895489

O=C(O)c1ccc(-c2cn(Cc3ccccc3)c(=O)n2Cc2ccc(CP(=O)(OF)OF)c(Br)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
MAPK10 P53779 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
RHEB Q15382 2/20 0.36
MAPK8 P45983 1/20 0.35
MCHR1 Q99705 1/20 0.34
MMP13 P45452 2/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
HDAC6 Q9UBN7 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
PLA2G4A P47712 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
HDAC11 Q96DB2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898669 1.00 ALDH1A1 (0.39) ALDH1A1MAPK10L3MBTL1RHEBMAPK8
SCHEMBL4901306 0.97 ALDH1A1 (0.39) ALDH1A1MAPK10L3MBTL1RHEBMAPK8
SCHEMBL4889733 0.94 ALDH1A1 (0.38) ALDH1A1MAPK10L3MBTL1RHEBMCHR1
SCHEMBL4898625 0.92 KDM4E (0.37) ALDH1A1MAPK10RHEBMCHR1HDAC6
SCHEMBL4903709 0.92 MAPK10 (0.42) ALDH1A1MAPK10L3MBTL1MAPK8MMP13
SCHEMBL4901331 0.92 MAPK10 (0.42) ALDH1A1MAPK10L3MBTL1MAPK8MMP13
SCHEMBL4901741 0.90 L3MBTL1 (0.37) ALDH1A1MAPK10L3MBTL1RHEBMMP13
SCHEMBL4901582 0.90 F2RL3 (0.43) ALDH1A1MAPK10L3MBTL1TSHR
SCHEMBL4901272 0.89 KDM4E (0.35) ALDH1A1MAPK10RHEBHDAC6TSHR
SCHEMBL4898674 0.89 ALDH1A1 (0.38) ALDH1A1MAPK10RHEBMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS ALDH1A1 3704/4885MAPK10 656/4885L3MBTL1 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.